Genetic testing for the clinician in prostate cancer

References

• Boström PJ, Bjartell AS, Catto JWF, et al. Genomic predictors of outcome in prostate cancer. Eur Urol. 2015;68(6):1033–1044.
   PubMed Web of Science ®Google Scholar
• Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–357.
   PubMed Web of Science ®Google Scholar
• Kumar A, Coleman I, Morrissey C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22(4):369–378.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012. CA Cancer J Clin. 2015:65(2):87–108. global cancer statistics - Search Results - PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/?term=globalcancerstatistics&page=1&pos=1
   PubMed Web of Science ®Google Scholar
• Larrañaga N, Galceran J, Ardanaz E, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010 May;21(SUPPL.3):iii83–89.
   PubMedGoogle Scholar
• Graif T, Loeb S, Roehl KA, et al. Under diagnosis and over diagnosis of prostate cancer. J Urol. 2007 Jul;178(1):88–92.
   PubMed Web of Science ®Google Scholar
• Gomez Gomez E, Salamanca Bustos JJ, Carrasco Valiente J, et al. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. BMJ Open. 2019 Nov;9(11):e031032–e031032.
   PubMed Web of Science ®Google Scholar
• Dani H, Loeb S. The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol. 2017;27(3):210–216.
   PubMed Web of Science ®Google Scholar
• Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019;37(4):286–295.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2: eRGPlus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016 Jul;70(1):45–53.
   PubMed Web of Science ®Google Scholar
• Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018;6(1):1.
   PubMedGoogle Scholar
• Cheng H, Powers J, Schaffer K, et al. Practical methods for integrating genetic testing into clinical practice for advanced prostate cancer. Am Soc Clin Oncol Educ B. 2018;38(38):372–381.
   PubMedGoogle Scholar
• Page EC, Bancroft EK, Brook MN, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019 Dec;76(6):831–842.
   PubMed Web of Science ®Google Scholar
• Das S, Salami SS, Spratt DE, et al. Bringing prostate cancer germline genetics into clinical practice. J Urol. 2019;202(2):223–230.
   PubMed Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Smit FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 2015 Jul;21(13):3061–3070.
   PubMed Web of Science ®Google Scholar
• Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker–based risk score. Eur Urol. 2016;70(5):740–748.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007 Jun;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):370–375.
   PubMed Web of Science ®Google Scholar
• McKiernan J, Donovan MJ, O’Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016 Jul;2(7):882–889.
   PubMed Web of Science ®Google Scholar
• Groskopf J, Aubin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006 Jun;52(6):1089–1095.
   PubMed Web of Science ®Google Scholar
• Auprich M, Bjartell A, Chun FKH, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011;60(5):1045–1054.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27):3659–3668.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Aubin SMJ, Siddiqui J, et al. Urine TMPRSS2: eRGfusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011 Aug;3(94):94.
   Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014 Mar;65(3):534–542.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650–1655.
   PubMed Web of Science ®Google Scholar
• Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-Kallikrein panel: an independent replication. J Clin Oncol. 2010 May;28(15):2493–2498.
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep;68(3):464–470.
   PubMed Web of Science ®Google Scholar
• Wojno KJ, Costa FJ, Cornell RJ, et al. Reduced rate of repeated prostate biopsies observed in ConfirmMDx clinical utility field study. Am Heal Drug Benefits. 2014;7(3):129–134.
   PubMedGoogle Scholar
• Hendriks RJ, van der Leest MMG, Dijkstra S, et al. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate. 2017 Oct;77(14):1401–1407.
   PubMed Web of Science ®Google Scholar
• Cucchiara V, Cooperberg MR, Dall’Era M, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572–582.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Carroll PR, Dall’Era MA, et al., the state of the science on prostate cancer biomarkers: the San Francisco consensus statement. Eur Urol. 2019;76(3):268–272.
   PubMed Web of Science ®Google Scholar
• Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446–1452.
   PubMed Web of Science ®Google Scholar
• Gramling R, Irvin JE, Nash J, et al. Numeracy and medicine: key family physician attitudes about communicating probability with patients [1]. J Am Board Family Pract. 2004;17(6):473.
   PubMedGoogle Scholar
• Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol. 2020 May 1;38(13):1474-1494.
   Google Scholar
• Kim HL, Li P, Huang HC, et al. Validation of the decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2019;22(3):399–405.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016;17(11):1612–1620.
   PubMed Web of Science ®Google Scholar
• Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550–560.
   PubMed Web of Science ®Google Scholar
• Spratt DE, Zhang J, Santiago-Jiḿenez M, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol. 2018;36(6):581–590.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Erho N, Chan JM, et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur Urol. 2018;74(4):444–452.
   PubMed Web of Science ®Google Scholar
• Hu JC, Tosoian JJ, Qi J, et al. Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer. JCO Precis Oncol. 2018;2:1–15.
   PubMed Web of Science ®Google Scholar
• Berlin A, Murgic J, Hosni A, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy. Int J Radiat Oncol Biol Phys. 2019;103(1):84–91.
   PubMed Web of Science ®Google Scholar
• Gore JL, Du Plessis M, Santiago-Jiménez M, et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017;123(15):2850–2859.
   PubMed Web of Science ®Google Scholar
• Marascio J, Spratt DE, Zhang J, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy.
   Google Scholar
• Spratt DE, Yousefi K, Deheshi S, et al. Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J Clin Oncol. 2017;35(18):1991–1998.
   PubMed Web of Science ®Google Scholar
• Dalela D, Santiago-Jiménez M, Yousefi K, et al. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: development and internal validation of a multivariable prognostic model. J Clin Oncol. 2017;35(18):1982–1990.
   PubMed Web of Science ®Google Scholar
• Feng FY, Sandler HM, Huang H-C, et al. Transcriptome profiling of NRG Oncology/RTOG 9601: validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. J Clin Oncol. 2020 Feb 19;38(6_suppl):276. Internet]. Available from.
   Web of Science ®Google Scholar
• Van Den Eeden SK, Lu R, Zhang N, et al. A Biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease [Figure presented]. Eur Urol. 2018;73(1):129–138.
   PubMed Web of Science ®Google Scholar
• Cullen J, Rosner IL, Brand TC, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68(1):123–131.
   PubMed Web of Science ®Google Scholar
• Kornberg Z, Cooperberg MR, Cowan JE, et al. A 17-gene genomic prostate score as a predictor of adverse pathology in men on active surveillance. J Urol. 2019;202(4):702–709.
   PubMedGoogle Scholar
• Eggener S, Karsh LI, Richardson T, et al. A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility. Urology. 2019;126:76–82.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428–1434.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113(3):382–389.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 2011;12(3):245–255.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(5):848–853.
   PubMed Web of Science ®Google Scholar
• Shore ND, Kella N, Moran B, et al. Impact of the cell cycle progression test on physician and patient treatment selection for localized prostate cancer. J Urol. 2016;195(3):612–618.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30(6):1025–1031.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Berman DM, Rimm DL, et al. Biology of Human Tumors Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res. 2015;21(11):2591–2600.
   PubMed Web of Science ®Google Scholar
• Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63(5):920–926.
   PubMed Web of Science ®Google Scholar
• Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 May 1;50(5):645–651.
   PubMed Web of Science ®Google Scholar
• Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;166(23):11428–11436.
   Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
   PubMed Web of Science ®Google Scholar
• Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523–528.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–453.
   PubMed Web of Science ®Google Scholar
• Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69(6):992–995.
   PubMed Web of Science ®Google Scholar
• Zafeiriou Z, Bianchini D, Chandler R, et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur Urol. 2019;75(1):184–192.
   PubMed Web of Science ®Google Scholar
• Pomerantz MM, Spisák S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123(18):3532–3539.
   PubMed Web of Science ®Google Scholar
• Marshall CH, Sokolova AO, McNatty AL, et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur Urol. 2019;76(4):452–458.
   PubMed Web of Science ®Google Scholar
• Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–174.
   PubMed Web of Science ®Google Scholar
• Abida W, Bryce AH, Vogelzang NJ, et al. 793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2018;29(suppl_8):viii272.
   Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2019;30:v881–2.
   PubMedGoogle Scholar
• Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025.
   PubMed Web of Science ®Google Scholar
• Castro E, Romero-Laorden N, Del Pozo A, et al., Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019:37(6): 490–503.
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2):186–193.
   PubMed Web of Science ®Google Scholar
• Leongamornlert D, Saunders E, Dadaev T, et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer. 2014;110(6):1663–1672.
   PubMed Web of Science ®Google Scholar
• Annala M, Struss WJ, Warner EW, et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer. Eur Urol. 2017;72(1):34–42.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74(2):218–225.
   PubMed Web of Science ®Google Scholar
• Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008;99(2):371–374.
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16(7):2115–2121.
   PubMed Web of Science ®Google Scholar
• Lozano R, Castro E, Piulats JM, et al. Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. J Clin Oncol. 2019 Feb 26;37(7_suppl):264.
   Google Scholar
• Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–243.
   PubMed Web of Science ®Google Scholar
• Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69(7):2912–2918.
   PubMed Web of Science ®Google Scholar
• Attard G, De Bono JS, Logothetis CJ, et al. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin Cancer Res. 2015;21(7):1621–1627.
   PubMed Web of Science ®Google Scholar
• Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011;60(5):897–904.
   PubMed Web of Science ®Google Scholar
• Grande E, Fernández Pérez MP, Font A, et al. Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: the PREMIERE study. Ann Oncol. 2016;27(suppl_6):vi247.
   Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–296.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006;66(16):7889–7898.
   PubMed Web of Science ®Google Scholar
• Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;1:1–16.
   Web of Science ®Google Scholar
• Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67(4):795–802.
   PubMed Web of Science ®Google Scholar
• Dyson NJ. RB1: A prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492–1502.
   PubMed Web of Science ®Google Scholar
• Aparicio AM, Shen L, Tapia ELN, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22(6):1520–1530.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297–303.
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):6320.
   Web of Science ®Google Scholar
• Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 – and RB1-deficient prostate cancer. Science. 2017;355(6320):6320.
   Web of Science ®Google Scholar
• Rodrigues DN, Casiraghi N, Romanel A, et al. Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25(2):687–697.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–6309.
   PubMed Web of Science ®Google Scholar
• Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13(23):7053–7058.
   PubMed Web of Science ®Google Scholar
• Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol. 2009;20(1):27–33.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10(3):233–239.
   PubMed Web of Science ®Google Scholar
• Lorente D, Olmos D, Mateo J, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol. 2016;70(6):985–992.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al., AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014:371(11): 1028–1038.
   PubMed Web of Science ®Google Scholar
• Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2(11):1441–1449.
   PubMed Web of Science ®Google Scholar
• Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol. 2017;71(6):874–882.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582–591.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J clin oncol. 2019;37(13):1120–1129.
   PubMed Web of Science ®Google Scholar
• Del Re M, Biasco E, Crucitta S et al., The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol Internet]. 2017;71(4):680–687.
   PubMed Web of Science ®Google Scholar
• Jenkins S, Yang JCH, Ramalingam SS, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer. J Thorac Oncol. 2017;12(7):1061–1070.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Laperriere G, Germain H. Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Sci Rep. 2017;7(1):1.
   PubMedGoogle Scholar
• Azad AA, Volik SV, Wyatt AW, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(10):2315–2324.
   PubMed Web of Science ®Google Scholar
• Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6(254):254.
   Web of Science ®Google Scholar
• Romanel A, Tandefelt DG, Conteduca V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7(312):1–9.
   Web of Science ®Google Scholar
• Salvi S, Casadio V, Conteduca V, et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer. 2015;112(10):1717–1724.
   PubMed Web of Science ®Google Scholar